INVO Fertility (NASDAQ:IVF) vs. Defiance Daily Target 2X Long LMND ETF (NASDAQ:LMNX) Head to Head Analysis

INVO Fertility (NASDAQ:IVF) and Defiance Daily Target 2X Long LMND ETF (NASDAQ:LMNX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, earnings, institutional ownership, analyst recommendations, risk and profitability.

Volatility and Risk

INVO Fertility has a beta of 2.33, indicating that its share price is 133% more volatile than the S&P 500. Comparatively, Defiance Daily Target 2X Long LMND ETF has a beta of -7.64, indicating that its share price is 864% less volatile than the S&P 500.

Valuation and Earnings

This table compares INVO Fertility and Defiance Daily Target 2X Long LMND ETF”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
INVO Fertility	$6.84 million	0.32	-$25.13 million	($3,151.46)	0.00
Defiance Daily Target 2X Long LMND ETF	$437.66 million	0.01	$15.17 million	$0.51	24.08

Defiance Daily Target 2X Long LMND ETF has higher revenue and earnings than INVO Fertility. INVO Fertility is trading at a lower price-to-earnings ratio than Defiance Daily Target 2X Long LMND ETF, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares INVO Fertility and Defiance Daily Target 2X Long LMND ETF’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
INVO Fertility	-183.75%	-420.62%	-45.21%
Defiance Daily Target 2X Long LMND ETF	5.39%	4.66%	2.91%

Analyst Recommendations

This is a summary of recent recommendations for INVO Fertility and Defiance Daily Target 2X Long LMND ETF, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
INVO Fertility	1	0	0	1	2.50
Defiance Daily Target 2X Long LMND ETF	0	0	0	0	0.00

INVO Fertility currently has a consensus price target of $20.00, indicating a potential upside of 1,512.90%. Given INVO Fertility’s stronger consensus rating and higher possible upside, research analysts plainly believe INVO Fertility is more favorable than Defiance Daily Target 2X Long LMND ETF.

Insider and Institutional Ownership

12.0% of INVO Fertility shares are owned by institutional investors. Comparatively, 87.8% of Defiance Daily Target 2X Long LMND ETF shares are owned by institutional investors. 0.7% of INVO Fertility shares are owned by insiders. Comparatively, 6.6% of Defiance Daily Target 2X Long LMND ETF shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Defiance Daily Target 2X Long LMND ETF beats INVO Fertility on 9 of the 14 factors compared between the two stocks.

About INVO Fertility

INVO Bioscience, Inc., together with its subsidiary, a healthcare services fertility company, provides assisted reproductive technology solutions worldwide. It offers INVOcell, a medical device that allows fertilization and early embryo development to take place in vivo within the woman’s body. The company was founded in 2007 and is based in Sarasota, Florida.

About Defiance Daily Target 2X Long LMND ETF

Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include Luminex 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; MicroPlex, MagPlex, xTAG, SeroMAP, and calibration and control microspheres; xPONENT, a software suite to simplify laboratory workflow and enhance productivity; and TDAS, an analysis program designed for development and optimization of nucleic acid assays. The company also provides xTAG assays and products to identify the causative agent for respiratory and gastrointestinal infections, as well as IVD kits for cystic fibrosis genotyping and pharmacogenetic assays used to profile genetic mutations related to drug metabolism; ARIES system, a sample to answer real-time PCR platform; SYNCT data management software solutions; and ARIES cassettes that are self-contained assay consumables, such as ARIES HSV 1&2 Assay, ARIES Flu A/B & RSV Assay, ARIES Group B Streptococcus Assay, ARIES Group A Strep Assay, ARIES Bordetella Assay, ARIES Norovirus Assay, ARIES C. difficile Assay, ARIES MRSA Assay, and SARS-CoV-2 Assay. In addition, it offers VERIGENE system, a semi-automated, multiplex, molecular analysis system for the clinical diagnostics market; VERIGENE test cartridges; Amnis FlowSight imaging flow cytometers; Amnis ImageStream Mark II imaging flow cytometers; Amnis CellStream for cell and particle analysis; Guava easyCyte benchtop flow cytometers; Muse cell analyzers; and IDEAS, an image analysis software. Luminex Corporation was founded in 1995 and is based in Austin, Texas.